Catalyst Event
Sanofi (SNY) · Other
From KEDI Global Longevity Bio Index (KGLB)
4/24/2026, 12:00:00 AM
The European Medicines Agency's CHMP recommended approval for tolebrutinib for multiple sclerosis on April 24, 2026. (Medium importance estimated as regulatory recommendations for key pipeline drugs often impact price by 5-10%) expected.
Korean Translation
2026년 4월 24일 유럽의약품청(EMA) 약물사용자문위원회(CHMP)가 다발성 경화증 치료제 톨레브루티닙의 승인을 권고함 (주요 약물의 승인 권고는 통상 5-10%의 주가 변동을 야기하므로 Medium으로 추정함). 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
FDA PDUFA target action date for LEQEMBI's subcutaneous autoinjector formulation (IQLIK SC-AI) for initiation dosing, a potential new administration option for the Alzheimer's disease treatment, scheduled for 2026-05-24. High impact expected due to the significant market potential of the Alzheimer's treatment.
5/24/2026, 12:00:00 AM
Thermo Fisher Scientific Inc (TMO) · Other
An Investor Day is scheduled for May 20, 2026, where senior management will provide presentations scheduled.
5/20/2026, 12:00:00 AM
Takeda Pharmaceutical Co Ltd (TAK) · Earnings Release
Takeda is scheduled to announce its financial results for the full fiscal year 2025 (ending March 31, 2026) on May 13, 2026. High importance is estimated as earnings reports for major pharmaceutical firms often trigger price movements exceeding 10% based on guidance. This event is scheduled.
5/13/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Q1 2026 earnings release is scheduled. Earnings announcements typically result in >5% price impact, scheduled.
5/7/2026, 12:00:00 AM
Viatris Inc (VTRS) · Earnings Release
Viatris is scheduled to report its first quarter 2026 financial results on May 7, 2026, with an estimated price impact of over 5% based on historical earnings volatility scheduled.
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to announce its first quarter 2026 financial results. Low importance as it is a routine earnings call, scheduled.
5/6/2026, 12:00:00 AM